These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

281 related articles for article (PubMed ID: 24048386)

  • 1. Clinical potential of cariprazine in the treatment of acute mania.
    Altınbaş K; Guloksuz S; Oral ET
    Psychiatr Danub; 2013 Sep; 25(3):207-13. PubMed ID: 24048386
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cariprazine (RGH-188), a dopamine D(3) receptor-preferring, D(3)/D(2) dopamine receptor antagonist-partial agonist antipsychotic candidate: in vitro and neurochemical profile.
    Kiss B; Horváth A; Némethy Z; Schmidt E; Laszlovszky I; Bugovics G; Fazekas K; Hornok K; Orosz S; Gyertyán I; Agai-Csongor E; Domány G; Tihanyi K; Adham N; Szombathelyi Z
    J Pharmacol Exp Ther; 2010 Apr; 333(1):328-40. PubMed ID: 20093397
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cariprazine, an orally active D2/D3 receptor antagonist, for the potential treatment of schizophrenia, bipolar mania and depression.
    Gründer G
    Curr Opin Investig Drugs; 2010 Jul; 11(7):823-32. PubMed ID: 20571978
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cariprazine in bipolar disorder: clinical efficacy, tolerability, and place in therapy.
    Citrome L
    Adv Ther; 2013 Feb; 30(2):102-13. PubMed ID: 23361832
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The efficacy and tolerability of cariprazine in acute mania associated with bipolar I disorder: a phase II trial.
    Durgam S; Starace A; Li D; Migliore R; Ruth A; Németh G; Laszlovszky I
    Bipolar Disord; 2015 Feb; 17(1):63-75. PubMed ID: 25056368
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cariprazine for the Treatment of Schizophrenia: A Review of this Dopamine D3-Preferring D3/D2 Receptor Partial Agonist.
    Citrome L
    Clin Schizophr Relat Psychoses; 2016; 10(2):109-19. PubMed ID: 27440212
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cariprazine, a new, orally active dopamine D2/3 receptor partial agonist for the treatment of schizophrenia, bipolar mania and depression.
    Veselinović T; Paulzen M; Gründer G
    Expert Rev Neurother; 2013 Nov; 13(11):1141-59. PubMed ID: 24175719
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cariprazine in schizophrenia: clinical efficacy, tolerability, and place in therapy.
    Citrome L
    Adv Ther; 2013 Feb; 30(2):114-26. PubMed ID: 23361833
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cariprazine:New dopamine biased agonist for neuropsychiatric disorders.
    De Deurwaerdère P
    Drugs Today (Barc); 2016 Feb; 52(2):97-110. PubMed ID: 27092339
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cariprazine in the treatment of acute mania in bipolar I disorder: a double-blind, placebo-controlled, phase III trial.
    Sachs GS; Greenberg WM; Starace A; Lu K; Ruth A; Laszlovszky I; Németh G; Durgam S
    J Affect Disord; 2015 Mar; 174():296-302. PubMed ID: 25532076
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cariprazine for the Treatment of Bipolar Disorder.
    Findlay LJ; El-Mallakh PL; El-Mallakh RS
    Perspect Psychiatr Care; 2017 Jul; 53(3):148-155. PubMed ID: 27059102
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Safety and tolerability of cariprazine in patients with acute exacerbation of schizophrenia: a pooled analysis of four phase II/III randomized, double-blind, placebo-controlled studies.
    Earley W; Durgam S; Lu K; Laszlovszky I; Debelle M; Kane JM
    Int Clin Psychopharmacol; 2017 Nov; 32(6):319-328. PubMed ID: 28692485
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cariprazine: chemistry, pharmacodynamics, pharmacokinetics, and metabolism, clinical efficacy, safety, and tolerability.
    Citrome L
    Expert Opin Drug Metab Toxicol; 2013 Feb; 9(2):193-206. PubMed ID: 23320989
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cariprazine for bipolar depression: What is the number needed to treat, number needed to harm and likelihood to be helped or harmed?
    Citrome L
    Int J Clin Pract; 2019 Oct; 73(10):e13397. PubMed ID: 31355510
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Tolerability of cariprazine in the treatment of acute bipolar I mania: A pooled post hoc analysis of 3 phase II/III studies.
    Earley W; Durgam S; Lu K; Debelle M; Laszlovszky I; Vieta E; Yatham LN
    J Affect Disord; 2017 Jun; 215():205-212. PubMed ID: 28343051
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cariprazine to Treat Schizophrenia and Bipolar Disorder in Adults.
    Edinoff A; Ruoff MT; Ghaffar YT; Rezayev A; Jani D; Kaye AM; Cornett EM; Kaye AD; Viswanath O; Urits I
    Psychopharmacol Bull; 2020 Sep; 50(4):83-117. PubMed ID: 33012874
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cariprazine (RGH-188), a potent D3/D2 dopamine receptor partial agonist, binds to dopamine D3 receptors in vivo and shows antipsychotic-like and procognitive effects in rodents.
    Gyertyán I; Kiss B; Sághy K; Laszy J; Szabó G; Szabados T; Gémesi LI; Pásztor G; Zájer-Balázs M; Kapás M; Csongor EÁ; Domány G; Tihanyi K; Szombathelyi Z
    Neurochem Int; 2011 Nov; 59(6):925-35. PubMed ID: 21767587
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy and Safety of Cariprazine in Acute Exacerbation of Schizophrenia: Results From an International, Phase III Clinical Trial.
    Kane JM; Zukin S; Wang Y; Lu K; Ruth A; Nagy K; Laszlovszky I; Durgam S
    J Clin Psychopharmacol; 2015 Aug; 35(4):367-73. PubMed ID: 26075487
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The safety and tolerability of cariprazine in patients with manic or mixed episodes associated with bipolar I disorder: A 16-week open-label study.
    Ketter TA; Sachs GS; Durgam S; Lu K; Starace A; Laszlovszky I; Németh G
    J Affect Disord; 2018 Jan; 225():350-356. PubMed ID: 28843918
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The Role of Dopamine D
    Huang M; He W; Kiss B; Farkas B; Adham N; Meltzer HY
    J Pharmacol Exp Ther; 2019 Nov; 371(2):517-525. PubMed ID: 31511365
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.